P276-00, A cyclin-dependent kinase inhibitor, Modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Shirsath, Nitesh P ^a   Manohar, Sonal M ^a   Joshi, Kalpana S ^a  

^a Piramal Enterprises Limited   (India)

Author keywords

Cdk inhibitors; Cyclin D1; Mantle cell lymphoma; Mcl 1; P276 00

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN T1; DOXORUBICIN; P 276 00; PROTEIN MCL 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MANTLE CELL LYMPHOMA; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL CYCLE; CELL LINE, TUMOR; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; FLAVONES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; LYMPHOMA, MANTLE-CELL; MICE; MICE, SCID; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; PYRAZINES; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84867493189     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-77     Document Type: Article

References (24)

1. Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol 2008, 142:149-165. 10.1111/j.1365-2141.2008.07124.x, 18410453.
2. Liu Q, Alinari L, Chen CS, Yan F, Dalton JT, Lapalombella R, Zhang X, Mani R, Lin T, Byrd JC, Baiocchi RA, Muthusamy N. FTY720 shows promising in vitro and in vivo preclinical activity by down modulating cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res 2010, 16:3182-3192. 10.1158/1078-0432.CCR-09-2484, 20460491.
3. Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood 2009, 114:1469-1476. 10.1182/blood-2009-02-179739, 19556426.
4. Norton AJ, Matthews J, Pappa V, Shamash J, Love S, Rohatiner AZ, Lister TA. Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 1995, 6:249-256.
5. Jourdan M, De Vos J, Mechti N, Klein B. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-a and insulin-like growth factor 1. Cell Death Differ 2000, 7:1244-1252. 10.1038/sj.cdd.4400758, 2423422, 11175262.
6. Venkataraman G, Maududi T, Ozpuyan F, Bahar HI, Izban KF, Qin JZ, Alkan S. Induction of apoptosis and down regulation of cell cycle protein in mantle cell lymphoma by flavopiridol treatment. Leuk Res 2006, 30:1377-1384. 10.1016/j.leukres.2006.03.004, 16624404.
7. Baran-Marszak F, Boukhiar M, Harel S, Laquillier C, Roger C, Gressin R, Martin A, Fagard R, Varin-Blank N, Ajchenbaum-Cymbalista F, Ledoux D. Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Haematologica 2010, 95:1865-1872. 10.3324/haematol.2009.019745, 2966908, 20663948.
8. Goy A, Feldman T. Expanding therapeutic options in mantle cell lymphoma. Clin Lymphoma Myeloma 2007, 7:S184-S191.
9. Chen R, Chubb S, Cheng T, Hawtin RE, Gandhi V, Plunkett W. Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Res 2010, 70:6587-6597. 10.1158/0008-5472.CAN-09-3578, 2929954, 20663900.
10. Pileri SA, Falini B. Mantle cell lymphoma. Haematologica 2009, 94:1488-1492. 10.3324/haematol.2009.013359, 2770958, 19880776.
11. Camacho E, Hernandez L, Hernandez S, Tort F, Bellosillo B, Bea S, Bosh F, Montserrat E, Cardesa A, Fernández PL, Campo E. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood 2002, 99:238-244. 10.1182/blood.V99.1.238, 11756177.
12. Hangaishi A, Ogawa S, Qiao Y, Wang L, Hosoya N, Yuji K, Imai Y, Takeuchi K, Miyawaki S, Hirai H. Mutations of Chk2 in primary hematopoietic neoplasms. Blood 2002, 99:3075-3077. 10.1182/blood.V99.8.3075, 11949635.
13. Tort F, Hernandez S, Bea S, Martinez A, Esteller M, Herman JG, Puig X, Camacho E, Sanchez M, Nayach I, Lopez-Guillermo A, Fernandez PL, Colomer D, Hernandez L, Campo E. CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. Blood 2002, 100:4602-4608. 10.1182/blood-2002-04-1078, 12393693.
14. de Boer CI, Krieken J, Schuuring E, Kluin PM. Bcl-1/cyclin D1 in malignant lymphoma. Ann Oncol 1997, 8:109-117.
15. Zukerberg LR, Benedict WF, Arnold A, Dyson N, Harlow E, Harris NL. Expression of the retinoblastoma protein in low-grade B-cell lymphoma: relationship to cyclin D1. Blood 1996, 88:268-276.
16. Jares P, Campo E, Pinyol M, Bosch F, Miquel R, Fernandez PL, Sanchez-Beato M, Soler F, Perez-Losada A, Nayach I, Mallofre C, Piris MA, Montserrat E, Cardesa A. Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. Am J Pathol 1996, 148:1591-1600. 1861570, 8623927.
17. Paoluzzi L, Scotto L, Marchi E, Zain J, Seshan VE, O'Connor OA. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res 2010, 16:554-565. 10.1158/1078-0432.CCR-09-1937, 20068080.
18. Bertoni F, Ponzoni M. The cellular origin of mantle cell lymphoma. Int J Biochem Cell Biol 2007, 39:1747-1753. 10.1016/j.biocel.2007.04.026, 17574898.
19. Khoury JD, Medeiros LJ, Rassidakis GZ, McDonnell TJ, Abruzzo LV, Lai R. Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression. J Pathol 2003, 199:90-97. 10.1002/path.1254, 12474231.
20. Joshi KS, Rathos MJ, Joshi RD, Sivakumar M, Mascarenhas M, Kamble S, Lal B, Sharma S. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther 2007, 6:918-925. 10.1158/1535-7163.MCT-06-0613, 17363486.
21. Joshi KS, Rathos MJ, Mahajan P, Wagh V, Shenoy S, Bhatia D, Chile S, Sivakumar S, Maier A, Fiebig HH, Sharma S. P276-00 a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther 2007, 6:926-934. 10.1158/1535-7163.MCT-06-0614, 17363487.
22. Manohar SM, Rathos MJ, Sonawane V, Rao SV, Joshi KS. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription. Leuk Res 2011, 35:821-830. 10.1016/j.leukres.2010.12.010, 21216463.
23. Manohar SM, Padgoankar A, Jalota-Badhwar A, Rao SV, Joshi KJ. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells. Prostate Cancer Prostatic Dis 2012, 15:15-27. 10.1038/pcan.2011.51, 22083267.
24. Chou TC. Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res 2010, 70:440-446. 10.1158/0008-5472.CAN-09-1947, 20068163.